Library
PubMed Central Open Access
research article
Professional
Open access

Risk of Acute Kidney Injury inEnteritis Compared WithEnteritis: A Retrospective Cohort Study

Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine

Open Forum Infectious DiseasesLast synced 8/3/2026Status: syncedPMID: 42542862 pmidDOI: 10.1093/ofid/ofag451

Abstract Background andare leading causes of bacterial gastroenteritis worldwide, yet their comparative impact on acute kidney injury (AKI) remains unexplored. s1 Methods We conducted a retrospective cohort study of adults (≥18 years) hospitalized with community-acquired bacterial gastroenteritis at a tertiary center in South Korea (2018–2025). The primary outcome was AKI incidence. Multivariable logistic regression assessed associations between pathogen type (,, or Others, includingor) and AKI risk (reference:). Secondary outcomes included postdischarge kidney outcomes (acute kidney disease [AKD], incident chronic kidney disease [CKD], and CKD progression). s2 Results Among 232 patients (n = 139,n = 55, and Others n = 38), AKI incidence differed significantly across groups (26.6%, 70.9%, and 31.6%, respectively;< .001), with 42% ofpatients developing AKI stages 2 and 3.enteritis was independently associated with higher AKI risk than(odds ratio 3.19, 95% confidence interval [CI] 1.23–8.30).patients had 46% longer hospital stays (median 8 vs 5 days). In-hospital AKI was associated with postdischarge composite kidney outcome (hazard ratio 3.17, 95% CI 1.02–9.83), particularly during the AKD window (7–90 days postdischarge). Notably, 17% of patients who recovered from AKI before discharge subsequently developed AKD or CKD. s3 Conclusions In this retrospective study, hospitalized patients withenteritis had a higher risk of AKI than those with; furthermore, those with in-hospital

Abstract

Abstract Background andare leading causes of bacterial gastroenteritis worldwide, yet their comparative impact on acute kidney injury (AKI) remains unexplored. s1 Methods We conducted a retrospective cohort study of adults (≥18 years) hospitalized with community-acquired bacterial gastroenteritis at a tertiary center in South Korea (2018–2025). The primary outcome was AKI incidence. Multivariable logistic regression assessed associations between pathogen type (,, or Others, includingor) and AKI risk (reference:). Secondary outcomes included postdischarge kidney outcomes (acute kidney disease [AKD], incident chronic kidney disease [CKD], and CKD progression). s2 Results Among 232 patients (n = 139,n = 55, and Others n = 38), AKI incidence differed significantly across groups (26.6%, 70.9%, and 31.6%, respectively;< .001), with 42% ofpatients developing AKI stages 2 and 3.enteritis was independently associated with higher AKI risk than(odds ratio 3.19, 95% confidence interval [CI] 1.23–8.30).patients had 46% longer hospital stays (median 8 vs 5 days). In-hospital AKI was associated with postdischarge composite kidney outcome (hazard ratio 3.17, 95% CI 1.02–9.83), particularly during the AKD window (7–90 days postdischarge). Notably, 17% of patients who recovered from AKI before discharge subsequently developed AKD or CKD. s3 Conclusions In this retrospective study, hospitalized patients withenteritis had a higher risk of AKI than those with; furthermore, those with in-hospital AKI from any cause were more likely to have adverse short-to-intermediate–term postdischarge kidney abnormalities. These findings support pathogen-specific risk stratification and the need for postdischarge monitoring of patients who develop in-hospital AKI. s4 In this retrospective cohort of 232 hospitalized adults with bacterial gastroenteritis,enteritis was associated with a 3.2-fold higher AKI risk than, and 17% of patients recovering from AKI subsequently developed acute kidney disease or chronic kidney disease, suggesting the potential benefit of continued postdischarge kidney monitoring. teaser

Educational only
This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.